25.59

0.79% 0.20

After Hours: 25.25 -0.34 -1.33%

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $25.59, with a volume of 296.38K. It is up +0.79% in the last 24 hours and up +12.48% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$25.39

Open:

$25.39

24h Volume:

296.38K

Relative Volume:

0.57

Market Cap:

$1.01B

Revenue:

$734.86M

Net Income/Loss:

$5.14M

P/E Ratio:

204.72

EPS:

0.125

Net Cash Flow:

$132.71M

1W Performance:

+1.99%

1M Performance:

+12.48%

6M Performance:

+1.11%

1Y Performance:

+10.21%

1-Day Range:

$25.00

$25.71

1-Week Range:

$24.43

$26.21

52-Week Range:

$18.80

$27.64

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

650-242-8052

Address

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Employee

829

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	25.59	998.26M	734.86M	5.14M	132.71M	0.125
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

Jul 01, 2026

UnitedHealthcare adds separate reimbursement for Exparel By Investing.com - Investing.com Australia

Jul 01, 2026

Deals tracker: Banner Health to sell facility to Quorum Health - Modern Healthcare News

Jul 01, 2026

Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView

Jul 01, 2026

Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer

Jul 01, 2026

Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings - marketscreener.com

Jul 01, 2026

PCRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus

Jul 01, 2026

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® - The Manila Times

Jul 01, 2026

Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance

Jul 01, 2026

Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView

Jul 01, 2026

Jun 30, 2026

Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com

Jun 30, 2026

Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet - TradingView

Jun 30, 2026

Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa

Jun 30, 2026

Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK

Jun 30, 2026

Pacira BioSciences Divests CryoTech to Zimmer Biomet - TipRanks

Jun 30, 2026

Pacira BioSciences Sells iovera° Device to Zimmer Biomet in $140 Million Deal, Focuses on Biopharma Innovation - Minichart

Jun 30, 2026

Pacira BioSciences to Sell Iovera Cryoanalgesia Business to Zimmer for Up to $140 Million - TradingView

Jun 30, 2026

Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan

Jun 30, 2026

Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan

Jun 30, 2026

Jun 29, 2026

PCRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 29, 2026

Pacira Biosciences, Inc. Actuals & Estimates (NASDAQ:PCRX) - TradingView

Jun 29, 2026

Price to book forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView

Jun 29, 2026

Enterprise value to EBIT forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView

Jun 29, 2026

Enterprise value to EBIT forward of Pacira Biosciences, Inc. – FWB:82P - TradingView

Jun 29, 2026

Price to sales forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView

Jun 29, 2026

Jun 28, 2026

Enterprise value to revenue forward of Pacira Biosciences, Inc. – FWB:82P - TradingView

Jun 28, 2026

Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Jun 28, 2026

Price to earnings forward of Pacira Biosciences, Inc. – FWB:82P - TradingView

Jun 28, 2026

Price to sales forward of Pacira Biosciences, Inc. – FWB:82P - TradingView

Jun 28, 2026

Jun 27, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSci - The National Law Review

Jun 27, 2026

Pacira BioSciences (PCRX) Gains 3.6% as Stock Approaches Key Resistance ZoneSocial Sentiment - dars.gov.et

Jun 27, 2026

Pacira Biosciences, Inc. Actuals & Estimates (FWB:82P) - TradingView

Jun 27, 2026

Jun 26, 2026

Pacira Biosciences, Inc. Actuals & Estimates (SWB:82P) - TradingView

Jun 26, 2026